In vitro study demonstrates one-step detection of cancer and cardiac biomarkers using hybrid gold-quantum dot nanostructures, highlighting a versatile platform for clinical diagnostics.
Recently, biosensing based on weak coupling in plasmon-emitter hybrid nanostructures exhibits the merits of simplicity and high sensitivity, and attracts increasing attention as an emerging nano-sensor. In this study, we propose an innovative plasmon-regulated fluorescence resonance energy transfer (plasmon-regulated FRET) sensing strategy based on a plasmon-emitter hybrid nanostructure of gold nanorod-quantum dots (Au NR-QDs) by partially modifying QDs onto the surfaces of Au NRs. The Au NR-QDs showed good sensitivity and reversibility against refractive index change. We successfully employed the Au NR-QDs to fabricate nano-sensors for detecting a cancer biomarker of alpha fetoprotein with a limit of detection of 0.30 ng/mL, which displays that the sensitivity of the Au NR-QDs nano-sensor was effectively improved compared with the Au NRs based plasmonic sensing. Additionally, to demonstrate the universality of the plasmon-regulated FRET sensing strategy, another plasmon-emitter hybrid nano-sensor of Au nano-prism-quantum dots (Au NP-QDs) were constructed and applied for detecting a myocardial infarction biomarker of cardiac troponin I. It was first reported that the change of absorption spectra of plasmonic structure in a plasmon-emitter hybrid nanostructure was employed for analytes detection. The plasmon-regulated FRET sensing strategy described herein has potential utility to develop general sensing platforms for chemical and biological analysis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: